GSK & LTZ Therapeutics Forge Strategic Alliance to Advance Myeloid Cell Engager Oncology Programmes

GSK (GSK) and LTZ Therapeutics have announced a strategic collaboration aimed at developing novel myeloid-cell engager (MCE) therapies in oncology, leveraging LTZ’s proprietary Myeloid Engager Platform.

LTZ’s platform is designed to harness the innate immune system by activating myeloid cells to phagocytose tumour cells, reprogram the tumour-microenvironment, enhance antigen presentation and engage adaptive immune responses. The approach offers potential advantages over T-cell engagers by tapping into the abundance of macrophages and other myeloid cells in many solid tumours and possibly reducing cytokine release risks. LTZ’s platform emphasises activation of innate cells with minimal pro-inflammatory cytokine release, enabling potent tumour cell killing with a more controlled immune-reaction profile.

While LTZ’s previous partnership with Eli Lilly and Company centred on autoimmune disease, the collaboration with GSK marks a clear pivot into oncology-focused therapeutics, complementing GSK’s existing oncology innovation strategy that spans blood cancers, gynaecologic cancers, tumour-cell targeting and immuno-oncology. By combining GSK’s global development and commercial capabilities with LTZ’s novel platform, the companies aim to accelerate first-in-class myeloid-cell engager assets towards the clinic and address high-unmet-need cancer indications.